E-viri
PDF
Recenzirano
Odprti dostop
-
Ménard, Didier; Khim, Nimol; Beghain, Johann; Adegnika, Ayola A; Shafiul-Alam, Mohammad; Amodu, Olukemi; Rahim-Awab, Ghulam; Barnadas, Céline; Berry, Antoine; Boum, Yap; Bustos, Maria D; Cao, Jun; Chen, Jun-Hu; Collet, Louis; Cui, Liwang; Thakur, Garib-Das; Dieye, Alioune; Djallé, Djibrine; Dorkenoo, Monique A; Eboumbou-Moukoko, Carole E; Espino, Fe-Esperanza-Caridad J; Fandeur, Thierry; Ferreira-da-Cruz, Maria-Fatima; Fola, Abebe A; Fuehrer, Hans-Peter; Hassan, Abdillahi M; Herrera, Socrates; Hongvanthong, Bouasy; Houzé, Sandrine; Ibrahim, Maman L; Jahirul-Karim, Mohammad; Jiang, Lubin; Kano, Shigeyuki; Ali-Khan, Wasif; Khanthavong, Maniphone; Kremsner, Peter G; Lacerda, Marcus; Leang, Rithea; Leelawong, Mindy; Li, Mei; Lin, Khin; Mazarati, Jean-Baptiste; Ménard, Sandie; Morlais, Isabelle; Muhindo-Mavoko, Hypolite; Musset, Lise; Na-Bangchang, Kesara; Nambozi, Michael; Niaré, Karamoko; Noedl, Harald; Ouédraogo, Jean-Bosco; Pillai, Dylan R; Pradines, Bruno; Quang-Phuc, Bui; Ramharter, Michael; Randrianarivelojosia, Milijaona; Sattabongkot, Jetsumon; Sheikh-Omar, Abdiqani; Silué, Kigbafori D; Sirima, Sodiomon B; Sutherland, Colin; Syafruddin, Din; Tahar, Rachida; Tang, Lin-Hua; Touré, Offianan A; Tshibangu-wa-Tshibangu, Patrick; Vigan-Womas, Inès; Warsame, Marian; Wini, Lyndes; Zakeri, Sedigheh; Kim, Saorin; Eam, Rotha; Berne, Laura; Khean, Chanra; Chy, Sophy; Ken, Malen; Loch, Kaknika; Canier, Lydie; Duru, Valentine; Legrand, Eric; Barale, Jean-Christophe; Stokes, Barbara; Straimer, Judith; Witkowski, Benoit; Fidock, David A; Rogier, Christophe; Ringwald, Pascal; Ariey, Frederic; Mercereau-Puijalon, Odile
The New England journal of medicine, 06/2016, Letnik: 374, Številka: 25Journal Article
The emergence of Plasmodium falciparum resistance to artemisinin-based therapy is a major global health challenge. In this report, investigators describe the distribution of K13-propeller polymorphisms, the basis of the majority of artemisinin resistance, in 59 countries. Increased efforts have substantially reduced the global burden of malaria caused by Plasmodium falciparum, 1 , 2 but the recent gains are threatened by emerging resistance to artemisinins, the cornerstone of current first-line combination treatment. 1 , 3 , 4 Artemisinins are active against a large range of intraerythrocytic developmental stages, but their usefulness is curtailed by ring-stage resistance. 5 , 6 Clinical artemisinin resistance, which was first documented in western Cambodia, 7 – 10 is now prevalent across Southeast Asia and South China. 11 – 17 Widespread artemisinin resistance would have dramatic consequences, since replacement therapies are limited and threatened by resistance. 18 – 22 Therapeutic efficacy studies are the standard method . . .
